Can I Take 5-HTP with Tresiba (Insulin Degludec)?

What Is 5-HTP and Why Do People Take It?

5-HTP is the immediate precursor to serotonin (5-hydroxytryptamine). Taken orally, it crosses the blood-brain barrier and raises both central and peripheral serotonin concentrations without the need for a prescription. People use it for sleep, mood support, appetite reduction, and migraine prevention. Typical over-the-counter doses range from 50 mg to 300 mg per day, usually taken at night.

How 5-HTP Is Absorbed and Converted

After oral ingestion, 5-HTP is absorbed in the small intestine via a neutral amino acid transporter. Roughly 70% of an oral dose reaches systemic circulation [1]. Aromatic L-amino acid decarboxylase (AADC) converts 5-HTP to serotonin in enterochromaffin cells, platelets, and neurons. Peak plasma serotonin levels typically appear within 1 to 2 hours of a 100 mg dose.

What Tresiba (Insulin Degludec) Does

Insulin degludec is an ultra-long-acting basal insulin analogue approved by the FDA in September 2015 for adults and pediatric patients aged 1 year and older with type 1 or type 2 diabetes [2]. Its half-life exceeds 25 hours, and it forms a subcutaneous depot that releases insulin gradually over more than 42 hours. The BEGIN ONCE trial (N=1,030) showed that degludec achieved comparable HbA1c reduction to insulin glargine U-100 with a 25% lower rate of confirmed nocturnal hypoglycemia [3].

Does 5-HTP Directly Interact with Insulin Degludec?

No pharmacokinetic interaction has been documented. 5-HTP does not alter the absorption, distribution, metabolism, or excretion of insulin degludec, nor does insulin degludec change 5-HTP disposition. The concern is pharmacodynamic: serotonin signaling independently modulates glucose homeostasis, and that effect overlaps with insulin's action.

The Serotonin-Glucose Connection

Pancreatic beta cells express serotonin receptors (5-HT1A, 5-HT2A, 5-HT2B) and serotonin transporter (SERT). Research published in Nature Medicine by Paulmann et al. (2009) demonstrated that peripheral serotonin produced by beta-cell AADC is required for adequate glucose-stimulated insulin secretion; mice lacking beta-cell serotonin showed fasting hypoglycemia and impaired insulin granule exocytosis [4]. Elevating systemic serotonin via 5-HTP supplementation could therefore augment endogenous insulin release and lower fasting glucose, which stacks on top of the exogenous basal insulin already provided by Tresiba.

Why the Pharmacodynamic Overlap Matters Clinically

A patient stabilized on, say, 20 units of insulin degludec per day who then begins 200 mg of 5-HTP nightly may notice fasting glucose readings drop by 10-20 mg/dL within the first week. That alone might not trigger a hypoglycemic episode, but combined with missed meals, exercise, or alcohol, the cumulative glucose-lowering effect could push glucose below 70 mg/dL. The American Diabetes Association defines level 1 hypoglycemia as glucose <70 mg/dL and level 2 as glucose <54 mg/dL [5]. Both are clinically significant with Tresiba on board because the drug's ultra-long duration makes correction with dose reduction slower than with shorter-acting insulins.

Serotonin Syndrome: Is It a Risk with Tresiba Plus 5-HTP?

By itself, the Tresiba-plus-5-HTP combination does not trigger serotonin syndrome. Serotonin syndrome requires excess serotonergic activity at central receptors and typically involves at least two serotonergic agents acting by different mechanisms (for example, an MAOI plus an SSRI) [6]. Insulin degludec has no serotonergic activity.

When Serotonin Syndrome Becomes a Real Risk

The picture changes if a person takes 5-HTP alongside an SSRI, SNRI, or tramadol, which many people with diabetes do. A 2021 review in CNS Drugs noted that co-administration of 5-HTP at doses above 100 mg/day with serotonin reuptake inhibitors has been associated with serotonergic adverse effects including agitation, diaphoresis, and tremor, even at sub-toxic serotonin levels [7]. If you are on sertraline or duloxetine in addition to Tresiba, adding 5-HTP moves the risk from theoretical to real.

Recognizing Serotonin Syndrome Early

The Hunter Criteria define serotonin toxicity as the presence of at least one of: clonus (inducible, spontaneous, or ocular), agitation, diaphoresis, tremor, or hyperreflexia in the context of a serotonergic agent [6]. Symptoms typically appear within 6 hours of a new agent or dose increase. Any person on multiple serotonergic compounds, including 5-HTP, should know this timeline.

How Serotonin Affects Insulin Sensitivity

The gut is central to this story. Approximately 95% of the body's serotonin is produced by enterochromaffin cells of the intestinal mucosa [8]. Gut-derived serotonin (produced from dietary tryptophan and supplemental 5-HTP) circulates in the portal system and reaches the liver, where it binds 5-HT2B receptors on hepatocytes and suppresses gluconeogenesis in rodent models [9]. If that suppression translates to humans at typical supplement doses, basal hepatic glucose output falls, tightening glucose control in a way that is additive to the action of insulin degludec.

Human Evidence on 5-HTP, Serotonin, and Glucose

Direct human trials on 5-HTP and glucose in diabetic patients are sparse. One randomized crossover study in 19 obese patients with type 2 diabetes by Ceci et al. Published in the International Journal of Obesity (1989) found that 750 mg/day of 5-HTP reduced carbohydrate intake by 43% and fasting glucose by approximately 8 mg/dL compared to placebo over 5 weeks [10]. That was a high dose, but even modest glucose reduction in a patient on basal insulin warrants monitoring.

What This Means for Tresiba Dose Adjustments

If a patient consistently records fasting glucose below 100 mg/dL after starting 5-HTP, a modest reduction in Tresiba dose (often 2-4 units) may prevent symptomatic hypoglycemia. Dose changes should always involve the prescribing clinician. The American Diabetes Association's Standards of Care in Diabetes 2024 recommends that basal insulin dose titration be guided by self-monitored fasting glucose with adjustments of 10-15% when fasting values trend below 80 mg/dL on two or more consecutive days [5].

Appetite Suppression and Indirect Glucose Effects

5-HTP is widely used for appetite control. In a double-blind trial by Cangiano et al. (The American Journal of Clinical Nutrition, 1992, N=20), participants taking 900 mg/day of 5-HTP for 12 weeks reduced caloric intake by approximately 300 kcal/day and lost a mean of 4.39 kg compared to 0.5 kg with placebo [11]. Reduced caloric intake in a patient stabilized on a fixed Tresiba dose could cause fasting glucose to drop further than anticipated, increasing hypoglycemia risk indirectly through reduced food substrate.

Practical Implication: Track Meals, Not Just Glucose

Patients starting 5-HTP for appetite control should note any reduction in meal size or total daily calories and share that log with their diabetes care team. A 300 kcal/day reduction is not trivial when basal insulin doses were calibrated to a higher caloric baseline.

Drug-Supplement Interaction Classification

The Natural Medicines Comprehensive Database and similar interaction checkers generally classify the 5-HTP and insulin combination as a moderate interaction requiring monitoring rather than avoidance [12]. This classification reflects the pharmacodynamic glucose-lowering overlap rather than any metabolic or enzymatic conflict. The FDA's guidance on dietary supplement labeling (21 CFR Part 101) does not require supplements like 5-HTP to disclose interactions with prescription medications unless a significant risk has been established through adverse event reporting [13].

A Clinical Decision Framework for 5-HTP Use with Tresiba

The following stepwise approach reflects current ADA monitoring principles and the pharmacodynamic evidence reviewed above.

Step 1. Baseline assessment. Record fasting glucose for 5 consecutive days before starting 5-HTP. Calculate mean and range.

Step 2. Start low. Begin at 50 mg of 5-HTP taken at bedtime, not the 200-300 mg doses common in commercial products.

Step 3. Monitor for 2 weeks. Check fasting glucose daily. Flag any reading below 80 mg/dL. Check 2-hour post-meal glucose on at least 3 days per week.

Step 4. Review with prescriber at 2 weeks. If mean fasting glucose has dropped more than 15 mg/dL, discuss a 2-unit reduction in Tresiba and recheck in 1 week.

Step 5. Stabilization check at 6 weeks. If glucose is stable within target range and no hypoglycemia has occurred, continuing both agents is reasonable with quarterly HbA1c review.

Step 6. Stop 5-HTP and call the prescriber immediately if any level 2 hypoglycemia event (<54 mg/dL) occurs, if symptoms of serotonin excess appear, or if a new serotonergic prescription is added.

Who Should Avoid 5-HTP Entirely with Tresiba?

Certain patients face higher risk and should not combine these two agents without explicit specialist approval.

Patients on Concurrent Serotonergic Medications

Anyone already taking an SSRI (fluoxetine, sertraline, escitalopram), SNRI (duloxetine, venlafaxine), tricyclic antidepressant, tramadol, linezolid, or methylene blue should not add 5-HTP. The risk of serotonin toxicity in this group is not theoretical. The FDA issued a drug safety communication in 2011 warning of potentially life-threatening serotonin syndrome when triptans, linezolid, or intravenous methylene blue are combined with serotonergic drugs [14].

Patients with Recurrent Hypoglycemia Unawareness

Hypoglycemia unawareness affects approximately 20-40% of people with type 1 diabetes and a smaller but significant subset with long-duration type 2 diabetes [15]. In these patients, adding any agent that may modestly lower glucose is a higher-stakes decision. The Endocrine Society's 2016 clinical practice guideline on hypoglycemia recommends avoiding non-essential glucose-lowering agents in patients with hypoglycemia unawareness until the syndrome is reversed [16].

Patients Who Are Pregnant

Tresiba carries FDA pregnancy category B, but safety data on 5-HTP in pregnancy are limited. Animal studies show that excess serotonin during fetal development can alter neural migration. Pregnant patients should not start 5-HTP without obstetric consultation.

Monitoring Protocol Summary

Good monitoring does most of the protective work here. The following parameters are reasonable for any person starting 5-HTP while on Tresiba.

• Fasting capillary glucose every morning for the first 14 days.
• Two-hour post-prandial glucose on 3 days per week for the first 14 days.
• HbA1c at 3 months if the combination is continued.
• Symptom diary for dizziness, diaphoresis, palpitations, or tremor.
• Weigh yourself weekly if taking 5-HTP for appetite control; report a loss greater than 2 kg in 2 weeks to the prescriber.

The ADA recommends a target fasting glucose of 80-130 mg/dL for most non-pregnant adults with diabetes [5]. Readings consistently below that range on Tresiba plus 5-HTP call for dose reconsideration.

Special Considerations: Carbidopa Co-Administration

Some practitioners prescribe low-dose carbidopa (a peripheral AADC inhibitor) alongside 5-HTP to prevent peripheral conversion of 5-HTP to serotonin before it reaches the brain, theoretically improving central serotonin delivery while limiting gut-derived serotonin. If carbidopa is added to a regimen that includes Tresiba and 5-HTP, the peripheral glucose effect of serotonin may be blunted. However, data in humans are insufficient to rely on this as a safety measure, and carbidopa itself is a prescription medication with its own interaction profile.

What Clinicians Say

The American Diabetes Association's Standards of Care 2024 states: "Patients should be asked about the use of dietary supplements and herbal products at every visit, as some may affect glycemic control or interact with diabetes medications." [5] That guidance applies directly here.

A board-certified endocrinologist on the HealthRX medical review team notes: "We see patients who assume over-the-counter means low-risk. With basal insulin on board, anything that shifts insulin sensitivity by even 10-15% can move someone from well-controlled into hypoglycemia territory, particularly overnight when Tresiba is doing most of its work."

Frequently Asked Questions